What question did this study set out to answer?

To explore the efficacy of antisense oligonucleotide as a selective JAK2 inhibitor in hematological malignancies.

December 8, 2025Blood

Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden

View Full Paper

Ask AI

Bookmark

Authors

Preclinical data shows antisense oligonucleotide reduced JAK2 protein in hematological malignancies, suggesting potential therapeutic benefits.

To explore the efficacy of antisense oligonucleotide as a selective JAK2 inhibitor in hematological malignancies.
Developed 19mer antisense oligonucleotides targeting JAK2 coding sequence.
Performed ASO treatment on HEL and SET2 cell lines with JAK2 V617F mutation.
Conducted qPCR and Western blot for JAK2 assessment after ASO administration.
Evaluated erythroid colony formation in PBMCs from PV patients post-ASO treatment.
ASO treatment led to ~50% reduction in JAK2 mRNA in HEL cells.
Achieved ~70% decrease in JAK2 protein levels in treated HEL cells.
Observed 35% reduction in pSTAT5, indicating effective inhibition of JAK2 signaling.
ERBC formation reduced in ASO-treated PV PBMCs, while non-erythroid colony formation was maintained.
Demonstrated selective inhibition of JAK2 without affecting JAK1, JAK3, or TYK2.

Przychodzen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Preclinical data shows antisense oligonucleotide reduced JAK2 protein in hematological malignancies, suggesting potential therapeutic benefits.

To explore the efficacy of antisense oligonucleotide as a selective JAK2 inhibitor in hematological malignancies.
Developed 19mer antisense oligonucleotides targeting JAK2 coding sequence.
Performed ASO treatment on HEL and SET2 cell lines with JAK2 V617F mutation.
Conducted qPCR and Western blot for JAK2 assessment after ASO administration.
Evaluated erythroid colony formation in PBMCs from PV patients post-ASO treatment.
ASO treatment led to ~50% reduction in JAK2 mRNA in HEL cells.
Achieved ~70% decrease in JAK2 protein levels in treated HEL cells.
Observed 35% reduction in pSTAT5, indicating effective inhibition of JAK2 signaling.
ERBC formation reduced in ASO-treated PV PBMCs, while non-erythroid colony formation was maintained.
Demonstrated selective inhibition of JAK2 without affecting JAK1, JAK3, or TYK2.

Przychodzen et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark